PharmacovigilanceOfficial

IGJ: Updating Abbott's FreeStyle Libre 3 app fixes security flaw and signal-loss issue

🇳🇱 IGJ · Tue 27 Oct 2026

The Dutch health inspectorate says the latest app version addresses a previously reported vulnerability and a signal-loss problem some users had after the previous update.

The Dutch Health and Youth Care Inspectorate (IGJ) has published an update on the FreeStyle Libre 3 app and the Libre app from Abbott. Users who install the latest version get fixes for two problems.

The first is the security vulnerability reported earlier for both apps. The second is a signal-loss problem that some users experienced after installing the previous update. The IGJ item does not describe the technical nature of either issue.

The notice is a manufacturer's warning, known as a Field Safety Notice (FSN), and is listed on the IGJ site as a three-page PDF. The manufacturer is Abbott Diabetes Care Ltd, and its authorised representative is Abbott BV. The FSN is dated 23 October 2026, while the IGJ listing shows a warning date of 28 October 2026.

The IGJ notes that manufacturers must monitor their devices after they reach the market and improve them where necessary. Where a risk to users exists, the manufacturer must act and inform both users and the inspectorate through an FSN.

What it means for your team

  • Manufacturers' corrective actions for software, including apps used with glucose-monitoring systems, are handled through the FSN process and appear in national authority listings.
  • Teams tracking Abbott's Libre apps should check the full FSN, dated 23 October 2026, for scope, affected versions and user instructions, none of which the IGJ summary gives.
  • The case shows that a software update can itself create a new issue, here signal loss, and that a further update may be needed to resolve it. This is relevant to post-market surveillance and change control.

Official source: IGJ ↗

Article written by VigiEye from the official source (IGJ). AI-assisted; check the source before acting.

More Pharmacovigilance All →